Phase 2 Multiple Sclerosis Trial, Recruiting NCT02521311 Sponsor: University of California, San Francisco Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, Recruiting

NCT02521311
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with, or are suspected to have, acute optic neuritis (inflammation of the optic nerve) in at least one eye, and your vision symptoms started no more than 3 weeks ago (not counting eye pain)
  • You are currently taking medication to manage a condition like multiple sclerosis — this does not automatically disqualify you
  • If you are a woman who could become pregnant, you are willing to use appropriate birth control throughout the trial
  • You are able to understand the study and sign a consent form agreeing to take part

Who may not be able to join:

  • You have another significant eye condition, such as diabetes-related eye disease, macular degeneration, glaucoma, or severe short-sightedness
  • There is bleeding at the optic disc (back of the eye) in the affected eye
  • You have no ability to perceive any light at all in the affected eye
  • Both eyes are affected by optic neuritis at the same time
  • There are certain specific changes visible in the affected eye (called cotton wool spots or a macular star) (confirm with trial site)
  • You have a history of a significant heart rhythm or electrical conduction problem
  • You have a history of cancer
  • You have had thoughts of suicide or suicidal behaviour in the past 6 months
  • You are pregnant, breastfeeding, or planning to become pregnant
  • You are already taking part in another clinical study, unless this has been approved in advance
  • You are already receiving another treatment specifically aimed at repairing the myelin (protective nerve coating) (confirm with trial site)
  • Your kidney function or liver function blood test results are above certain levels (confirm with trial site)
  • You have had a problem with drug or alcohol misuse in the past year
  • You have untreated vitamin B12 deficiency or untreated underactive thyroid
  • You have a significant ongoing illness affecting the heart, liver, kidneys, lungs, immune system, mental health, or other major body systems that the trial doctor believes could affect your safety or the study results
  • You test positive for a specific antibody associated with a condition called neuromyelitis optica (NMO) within the first 2 weeks after being enrolled in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ari Green, MD, MCR, University of California, San Francisco

Phone: 415.353.2707

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
28 February 2017
Est. completion
1 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in P100 latency on full-field visual evoked potential; Change in low contrast visual acuity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov